Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 18;10(2):186-194.
doi: 10.1093/nop/npac074. eCollection 2023 Apr.

Review of 20 years of adult medulloblastoma treatment: Chemotherapy prescription trends and survival

Marissa Sherwood  1   2 , Seth Climans  3 , Ronald Ramos  3 , Normand J Laperriere  1   2 , Andrew F Gao  4 , Barbara-Ann Millar  1   2 , David B Shultz  1   2 , Derek S Tsang  1   2 , Warren P Mason  3
Affiliations

Review of 20 years of adult medulloblastoma treatment: Chemotherapy prescription trends and survival

Marissa Sherwood et al. Neurooncol Pract. .

Abstract

Background: The historic standard of care for adult medulloblastoma has been considered surgery and radiation, while chemotherapy is increasingly being prescribed. This study reviewed 20-year chemotherapy trends at a high-volume center, as well as overall and progression free-survival.

Methods: Adults with medulloblastoma treated at an academic center from January 1, 1999 to -December 31, 2020 were reviewed. Patient baseline data were summarized and Kaplan-Meier estimators were used for survival.

Results: Forty-nine patients were included; median age was 30 years and male: female ratio was 2:1. Desmoplastic and classical histologies were most common. Of all patients, 23 (47%) were high risk and 7 (14%) metastatic at diagnosis. Only 10 (20%) received initial chemotherapy, of which 70% were high risk and 30% metastatic, with most treated from 2010 to 2020. Forty percent of initial chemotherapy patients received salvage chemotherapy for recurrence or metastases (of all patients, 49% required salvage). Initial chemotherapy regimens were mainly cisplatin/lomustine/vincristine, and at recurrence cisplatin/etoposide. Median overall survival was 8.6 years (95% CI 7.5-∞), with 1-, 5-, and 10-year survival at 95.8%, 72%, and 46.7%. Median overall survival for those who did not receive initial chemotherapy was 12.4 years and 7.4 years for those who did (P-value .2).

Conclusions: Twenty years of adult medulloblastoma treatment was reviewed. Initial chemotherapy patients, most of whom were high risk, trended towards worse survival, but this was nonsignificant. The ideal timing and choice of chemotherapy for adult medulloblastoma is unknown-challenges of administering chemotherapy following photon craniospinal irradiation may have prevented it from becoming routine.

Keywords: adult; chemotherapy; medulloblastoma; radiation; retrospective cohort study.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier plot of overall survival for 49 adult patients with medulloblastoma treated at the Princess Margaret Cancer Centre (PM) between January 1, 1999 and December 30, 2020.
Figure 2.
Figure 2.
Kaplan–Meier plots of overall survival of adult patients who received (dashed line) and who did not receive chemotherapy (solid line) as part of their initial treatment for medulloblastoma at the Princess Margaret Cancer Centre (PM) between January 1, 1999 and December 30, 2020; P-value .2.
Figure 3.
Figure 3.
Kaplan–Meier plots of overall survival of high risk (solid line) and average risk (dashed line) adult patients with medulloblastoma treated at the Princess Margaret Cancer Centre (PM) between January 1, 1999 and December 30, 2020; P-value .6.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012;19(11):1541–1544. - PubMed
    1. Walker EV, Davis FG. Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013. Neuro Oncol. 2019;21(3):360–369. - PMC - PubMed
    1. Abacioglu U, Uzel O, Sengoz M, Turkan S, Ober A. Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys. 2002;54(3):855–860. - PubMed
    1. Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer. 2007;110(9):2035–2041. - PubMed
    1. Kann BH, Lester-Coll NH, Park HS, et al. . Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro Oncol. 2017;19(2):259–269. - PMC - PubMed